Sign In
Buy LPCN
$2.12
+0.0100 (+0.474%)
At Close: Jul 31, 2026
SALT LAKE CITY , June 23, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutic
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
08:00am, Monday, 09'th Jun 2025
New Drug Submission filed by Lipocine's licensing partner Verity Pharma Over 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large comme
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
08:00am, Thursday, 22'nd May 2025
SALT LAKE CITY , May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
08:00am, Wednesday, 14'th May 2025
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
08:00am, Thursday, 08'th May 2025
SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
08:00am, Tuesday, 06'th May 2025
SALT LAKE CITY , May 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
08:00am, Wednesday, 26'th Mar 2025
48 hour at-home dosing Patient dosing expected in Q2/2025 SALT LAKE CITY , March 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technolog
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
08:00am, Thursday, 13'th Mar 2025
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral
Lipocine Announces FDA Labeling Changes for Testosterone Products
08:00am, Wednesday, 12'th Mar 2025
SALT LAKE CITY , March 12, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
08:00am, Thursday, 06'th Feb 2025
SALT LAKE CITY , Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
08:00am, Tuesday, 17'th Dec 2024
SALT LAKE CITY , Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral d
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
08:00am, Monday, 18'th Nov 2024
SALT LAKE CITY , Nov. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral d
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
08:00am, Thursday, 07'th Nov 2024
SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
08:00am, Thursday, 31'st Oct 2024
SALT LAKE CITY , Oct. 31, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral d
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
08:00am, Thursday, 10'th Oct 2024
Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GABAA modulation Rapid and durable CNS target engagem
